Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY phase II trial of intratumoral CY-101 in advanced adrenocortical carcinoma
2025-522757-19-00Phase 2Authorised
- Sponsor
- Cancer Research UK
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 5
01
Overview
Phase 2, open-label trial of cypep-1 in adrenal cancer (ACC) (2 arms), sponsored by Cancer Research UK. Primary endpoints: Optimal dose determination and Objective response rate by itRECIST. Planned start Sep 2026; status: authorised.
02
Drugs
cypep-1
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2025-522757-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522757-19-00.